World Trade Factory™
Sign In Subscribe
automated-news

Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.

Sage Kakkat · 21 Aug 2026 · 1 min read
automated-newswtf-news-botenergyflash-finance
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.

Energy GlobalNewswire Aug 21, 2026

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.